Human hepatic UGT2B15 developmental expression

Toxicological Sciences

Volumn 141, Issue 1, 2014, Pages 292-299

  Divakaran, Karthika ^a   Hines, Ronald N ^a,b   McCarver, D Gail ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

hepatic liver microsomes; ontogeny; single nucleotide polymorphism; SNP; UGT; uridine diphosphate glucuronosyltransferase

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; GENOMIC DNA; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 2B15; UNCLASSIFIED DRUG; UDP-GLUCURONOSYLTRANSFERASE 2B15, HUMAN;

ADOLESCENT; ADULT; ALLELE; ARTICLE; CHILD; DEVELOPMENT; EMBRYO; FEMALE; FETUS; GENETIC DIFFERENCE; GENOTYPE; GESTATIONAL AGE; HUMAN; HUMAN TISSUE; INFANT; LIVER MICROSOME; MALE; NEWBORN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PREGNANCY; PROTEIN CONTENT; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; WESTERN BLOTTING; EMBRYOLOGY; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; LIVER; ORGANOGENESIS; PRESCHOOL CHILD; SEXUAL DEVELOPMENT;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GESTATIONAL AGE; GLUCURONOSYLTRANSFERASE; HUMANS; INFANT; INFANT, NEWBORN; LIVER; MALE; MICROSOMES, LIVER; ORGANOGENESIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PREGNANCY; SEX CHARACTERISTICS;

EID: 84913616941     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfu126     Document Type: Article

References (45)

1. Alam, S. N., Roberts, R. J. and Fischer, L. J. (1977). Age-related differences in salicylamide and acetaminophen conjugation in man. J. Pediatr. 90, 130-135.
2. Anderson, B. J., McKee, A. D. andHolford,N. H. (1997). Size,myths and the clinical pharmacokinetics of analgesia in paediatric patients. Clin. Pharmacokinet. 33, 313-327.
3. Burchell, B., Coughtrie, M., Jackson, M., Harding, D., Fournel- Gigleux, S., Leakey, J. and Hume, R. (1989). Development of human liver UDP-glucuronosyltransferases. Dev. Pharmacol. Ther. 13, 70-77.
4. Cereghini, S. (1996). Liver-enriched transcription factors and hepatocyte differentiation. FASEB J. 10, 267-282.
5. Chung, J. Y., Cho, J. Y., Yu, K. S., Kim, J. R., Jung, H. R., Lim, K. S., Jang, I. J. and Shin, S. G. (2005). Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers. Clin. Pharmacol. Ther. 77, 486-494.
6. Coughtrie, M. W., Burchell, B., Leakey, J. E. and Hume, R. (1988). The inadequacy of perinatal glucuronidation: Immunoblot analysis of the developmental expression of individual UDPglucuronosyltransferase isoenzymes in rat and human liver microsomes. Mol. Pharmacol. 34, 729-735.
7. Court, M. H., Duan, S. X., Guillemette, C., Journault, K., Krishnaswamy, S., von Moltke, L. L. and Greenblatt, D. J. (2002). Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metab. Dispos. 30, 1257-1265.
8. Court, M. H., Hao, Q., Krishnaswamy, S., Bekaii-Saab, T., Al- Rohaimi, A., von Moltke, L. L. and Greenblatt, D. J. (2004). UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver. J. Pharmacol. Exp. Ther. 310, 656-665.
9. Court,M. H., Zhang, X., Ding, X., Yee, K. K., Hesse, L.M. and Finel, M. (2012). Quantitative distribution of mRNAs encoding the 19 human UDP-glucuronosyltransferase enzymes in 26 adult and 3 fetal tissues. Xenobiotica 42, 266-277.
10. de Wildt, S. N., Kearns, G. L., Leeder, J. S. and van den Anker, J. N. (1999). Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin. Pharmacokinet. 36, 439-452.
11. Domoradzki, J. Y., Thornton, C. M., Pottenger, L. H., Hansen, S. C., Card, T. L., Markham, D. A., Dryzga, M. D., Shiotsuka, R. N. and Waechter, J. M., Jr (2004). Age and dose dependency of the pharmacokinetics and metabolism of bisphenol A in neonatal sprague-dawley rats following oral administration. Toxicol. Sci. 77, 230-242.
12. Ekstrom, L., Johansson, M. and Rane, A. (2013). Tissue distribution and relative gene expression of UDPglucuronosyltransferases (2B7, 2B15, 2B17) in the human fetus. Drug Metab. Dispos. 41, 291-295.
13. Fallon, J. K., Neubert, H., Hyland, R., Goosen, T. C. and Smith, P. C. (2013). Targeted quantitative proteomics for the analysis of 14 UGT1As and -2Bs in human liver using NanoUPLC-MS/MS with selected reaction monitoring. J. Proteome. Res. 12, 4402- 4413.
14. Gallagher, C. J., Balliet, R. M., Sun, D., Chen, G. and Lazarus, P. (2010). Sex differences in UDP-glucuronosyltransferase 2B17 expression and activity. Drug Metab. Dispos. 38, 2204-2209.
15. Greenblatt, D. J., Divoll, M., Harmatz, J. S. and Shader, R. I. (1980). Oxazepam kinetics: Effects of age and sex. J. Pharmacol. Exp. Ther. 215, 86-91.
16. Hanioka, N., Naito, T. and Narimatsu, S. (2008). Human UDPglucuronosyltransferase isoforms involved in bisphenol A glucuronidation. Chemosphere 74, 33-36.
17. Hanioka, N., Oka, H., Nagaoka, K., Ikushiro, S. and Narimatsu, S. (2011). Effect of UDP-glucuronosyltransferase 2B15 polymorphism on bisphenol A glucuronidation. Arch. Toxicol. 85, 1373-1381.
18. He, X., Hesse, L. M., Hazarika, S., Masse, G., Harmatz, J. S., Greenblatt, D. J. and Court, M. H. (2009). Evidence for oxazepam as an in vivo probe of UGT2B15: Oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion. Br. J. Clin. Pharmacol. 68, 721-730.
19. Hines, R. N. (2008). The ontogeny of drug metabolism enzymes and implications for adverse drug events. Pharmacol. Ther. 118, 250-267.
20. Kiang, T. K., Ensom, M. H. and Chang, T. K. (2005). UDPglucuronosyltransferases and clinical drug-drug interactions. Pharmacol. Ther. 106, 97-132.
21. Kim, Y. H., Kim, C. S., Park, S., Han, S. Y., Pyo, M. Y. and Yang, M. (2003). Gender differences in the levels of bisphenol A metabolites in urine. Biochem. Biophys. Res. Commun. 312, 441- 448.
22. Klick, D. E., Shadley, J. D. and Hines, R. N. (2008). Differential regulation of human hepatic flavin containing monooxygenase 3 (FMO3) by CCAAT/enhancer-binding protein beta (C/EBPbeta) liver inhibitory and liver activating proteins. Biochem. Pharmacol. 76, 268-278.
23. Koukouritaki, S. B., Simpson, P., Yeung, C. K., Rettie, A. E. and Hines, R. N. (2002). Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression. Pediatr. Res. 51, 236-243.
24. Leakey, J. E., Hume, R. and Burchell, B. (1987). Development of multiple activities of UDP-glucuronyltransferase in human liver. Biochem. J. 243, 859-861.
25. Levesque, E., Beaulieu, M., Green, M. D., Tephly, T. R., Belanger, A. and Hum, D. W. (1997). Isolation and characterization of UGT2B15(Y85): A UDP-glucuronosyltransferase encoded by a polymorphic gene. Pharmacogenetics 7, 317-325.
26. MacKenzie, P. I., Hu, D. G. and Gardner-Stephen, D. A. (2010). The regulation of UDP-glucuronosyltransferase genes by tissue-specific and ligand-activated transcription factors. Drug Metab. Rev. 42, 99-109.
27. Martinez-Jimenez, C. P., Gomez-Lechon, M. J., Castell, J. V. and Jover, R. (2005). Transcriptional regulation of the human hepatic CYP3A4: Identification of a new distal enhancer region responsive to CCAAT/enhancer-binding protein beta isoforms (liver activating protein and liver inhibitory protein). Mol. Pharmacol. 67, 2088-2101.
28. Miners, J. O. and MacKenzie, P. I. (1991). Drug glucuronidation in humans. Pharmacol. Ther. 51, 347-369.
29. Miyagi, S. J. and Collier, A. C. (2007). Pediatric development of glucuronidation: The ontogeny of hepatic UGT1A4. Drug Metab. Dispos. 35, 1587-1592.
30. Miyagi, S. J., Milne, A. M., Coughtrie, M. W. and Collier, A. C. (2012). Neonatal development of hepatic UGT1A9: Implications of pediatric pharmacokinetics. Drug Metab. Dispos. 40, 1321-1327.
31. Nahar, M. S., Liao, C., Kannan, K. and Dolinoy, D. C. (2013). Fetal liver bisphenol A concentrations and biotransformation gene expression reveal variable exposure and altered capacity for metabolism in humans. J. Biochem. Mol. Toxicol. 27, 116- 123.
32. Nishiyama, T., Ogura, K., Nakano, H., Ohnuma, T., Kaku, T., Hiratsuka, A., Muro, K. and Watabe, T. (2002). Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases. Biochem. Pharmacol. 63, 1817-1830.
33. Nong, A., McCarver, D. G., Hines, R. N. and Krishnan, K. (2006). Modeling interchild differences in pharmacokinetics on the basis of subject-specific data on physiology and hepatic CYP2E1 levels: A case study with toluene. Toxicol. Appl. Pharmacol. 214, 78-87.
34. Odom,D. T., Zizlsperger,N., Gordon,D. B., Bell, G.W., Rinaldi,N. J., Murray, H. L., Volkert, T. L., Schreiber, J., Rolfe, P. A., Gifford, D. K., et al. (2004). Control of pancreas and liver gene expression by HNF transcription factors. Science 303, 1378-1381.
35. Ohno, S. and Nakajin, S. (2009). Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab. Dispos. 37, 32-40.
36. Ourlin, J. C., Jounaidi, Y., Maurel, P. and Vilarem, M. J. (1997). Role of the liver-enriched transcription factors C/EBP alpha and DBP in the expression of human CYP3A4 and CYP3A7. J. Hepatol. 26(Suppl. 2), 54-62.
37. Pacifici, G. M., Sawe, J., Kager, L. and Rane, A. (1982). Morphine glucuronidation in human fetal and adult liver. Eur. J. Clin. Pharmacol. 22, 553-558.
38. Patel, M., Tang, B. K., Grant, D. M. and Kalow,W. (1995). Interindividual variability in the glucuronidation of (S) oxazepamcontrasted with that of (R) oxazepam. Pharmacogenetics 5, 287- 297.
39. Richter, C. A., Birnbaum, L. S., Farabollini, F., Newbold, R. R., Rubin, B. S., Talsness, C. E., Vandenbergh, J. G.,Walser-Kuntz, D. R. and vom Saal, F. S. (2007). In vivo effects of bisphenol A in laboratory rodent studies. Reprod. Toxicol. 24, 199-224.
40. Stingl, J. C., Bartels, H., Viviani, R., Lehmann, M. L. and Brockmoller, J. (2013). Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review. Pharmacol. Ther. 141, 92-116.
41. Strassburg, C. P., Strassburg, A., Kneip, S., Barut, A., Tukey, R. H., Rodeck, B. and Manns,M. P. (2002). Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut 50, 259-265.
42. Teeguarden, J. G., Waechter, J. M., Jr, Clewell, H. J., III, Covington, T. R. and Barton, H. A. (2005). Evaluation of oral and intravenous route pharmacokinetics, plasma protein binding, and uterine tissue dose metrics of bisphenol A: A physiologically based pharmacokinetic approach. Toxicol. Sci. 85, 823- 838.
43. Tukey, R. H. and Strassburg, C. P. (2000). Human UDPglucuronosyltransferases: Metabolism, expression, and disease. Annu. Rev. Pharmacol. Toxicol. 40, 581-616.
44. Turgeon, D., Carrier, J. S., Levesque, E., Hum, D. W. and Belanger, A. (2001). Relative enzymatic activity, protein stability, and tissue distribution of human steroid-metabolizing UGT2B subfamily members. Endocrinology 142, 778-787.
45. Weiss, C. F., Glazko, A. J. andWeston, J. K. (1960). Chloramphenicol in the newborn infant. A physiologic explanation of its toxicity when given in excessive doses. N. Engl. J. Med. 262, 787-794.